Dirk Hoenemann, M.D.

Mar 31, 2021View PDF

Mr. Hoenemann has over 20 years of experience in clinical research, translational medicine, academia, and the pharmaceutical industry. He published numerous journals and articles in relation to first-in-human initiatives with novel antibody formats in hematological malignancies and solid tumors.

Mr. Hoenemann made substantial contributions to CAR-T study targeting Lewis-Y antigen.